Myeloma is a neoplastic disease of cells in the B-lymphocyte lineage, with a peak incidence in individuals 70 to 80 years old. Although the median age at diagnosis is 70 years , it is not uncommon for the disease to be diagnosed in much younger patients. An estimated 13,500 new cases of multiple myeloma were diagnosed in the United States in 1992. Little improvement in 5-year survival rates has occurred since the mid-1970s.
Myeloma has a distinct racial distribution, with incidence and death rates in American blacks nearly double those in whites . In fact, myeloma represents the most common (30%) of all lymphoreticular malignancies in the American black population .
The etiology of myeloma has remained obscure. Hereditary factors, radiation exposure, agricultural exposure, and antigenic stimulation have all been implicated to some extent. Support for the theory of antigenic stimulation has come from the discovery that some myeloma paraproteins show antibody activity against specific antigens . Also supporting this theory is the fact that, in murine models, the ability to induce peritoneal plasmacytomas is vastly reduced when the mice are raised in a germ-free environment .
Recent research has begun to elucidate the cellular and molecular derangements involved in the pathogenesis of multiple myeloma. These advances, in turn, have suggested novel approaches to treatment.
Renewable "Stem-Cell" Compartment
Although the terminally differentiated B-lymphocyte, the plasma cell, is the morphologically identifiable cell in myeloma, it represents the end-stage, nonproliferating cell compartment. It has been well documented that there are also monoclonal, early-stage B-cells circulating in the peripheral blood, and that these cells bear the same unique idiotype (clonally rearranged immunoglobulin genes) as the malignant plasma cells . Accumulating evidence suggests that the clonal B-cells may represent the renewable "stem-cell" compartment in myeloma.
Myeloma tumor cells have been well characterized by extensive phenotypic analysis. The cells in the circulating "stem-cell" pool express the B-cell markers CD19, CD20, and CD24. They also express the pre-B-cell markers CD10 (CALLA) and CD9 (an activated lymphocyte marker), as well as the plasma cell marker PCA-1. A subset express CD5 (an activation marker expressed on T-cells). This profile is consistent with differentiating, late-stage B-cells.
Aside from the fact that they are monoclonal, these "stem cells" differ from normal B-cells in that they express adhesion molecules, as well as other molecules known to play a role in cell motility, extravasation, and invasion, such as CD11b. These data are consistent with the hypothesis that myeloma originates with the transformation of a B-cell precursor in an extramedullary site, with subsequent migration of late-stage B-cells through the peripheral blood to the bone marrow, where the terminal stages of maturation to the plasma cell occur. The bone marrow microenvironment, with its collection of stromal cells, extracellular matrix glycoproteins, and many cytokines, is apparently very conducive for the maturation of malignant B-cells to plasma cells, leading to further disease expansion and progression.
Assays have been developed that take advantage of the fact that the "stem-cell" compartment in myeloma is identifiable by the unique immunoglobulin gene rearrangement of the malignant clone. Bird et al described their findings using a polymerase chain reaction (PCR)-based technique that employs consensus primers to amplify the rearranged locus of the immunoglobulin heavy-chain gene . They followed six myeloma patients in clinical complete remission after allogeneic bone marrow transplantation.
All patients were PCR positive within the first year after bone marrow transplantation. One patient became PCR negative at 1 year after transplantation, and two others at 2 and 4.5 years post-transplantation, respectively. These investigators concluded that PCR positivity up to 1 year after marrow transplantation is common, and is not necessarily predictive of relapse.
The significance of residual clonally rearranged cells is not completely understood at this time. Elucidation of this phenomenon will require further study of more cases with longer follow-up. The goal of such efforts is to identify patients who may benefit from additional therapeutic intervention after bone marrow transplantation.
There appear to be both qualitative and quantitative abnormalities in immunoregulatory T-cells in myeloma patients. The ratio of CD4 to CD8 cells is decreased on presentation and continues to decline with disease progression. T-cells with membrane receptors specific for both the idiotype and isotype of the immunoglobulin have been found in myeloma patients. These T-cells can bind to and suppress human myeloma cell lines in vitro.
Sensitive molecular techniques have revealed clonal T-cell populations in myeloma patients . However, the relevance of these clonal T-cells is unknown.
Recently, Massaia et al demonstrated anti-plasma-cell activity in bone marrow mononuclear cells from myeloma patients stimulated with the anti-CD3 monoclonal antibody OKT3 . A greater understanding of the role of immunoregulatory cells in myeloma should set the stage for targeted therapeutic interventions.
Dysregulation of Interleukin-6
The progression of myeloma depends greatly on growth factors, specifically, interleukin-6 (IL-6). In murine model systems, dysregulated IL-6 production can lead to various plasma-cell proliferative disorders, including plasmacytomas and Castleman's disease .
An overproduction of IL-6 is found in 37% of myeloma patients at diagnosis, and is associated with a poor prognosis.11 Initial work suggested that IL-6 was an autocrine growth factor, produced by the myeloma tumor cells themselves . However, more recent data suggest that marrow stromal overproduction of IL-6 is more important in myeloma .
The study of critical paracrine and autocrine loops in disease progression can help identify targets for novel therapeutic approaches. A recent case report from France described a patient with refractory myeloma in whom monoclonal anti-IL-6 antibodies produced an impressive, albeit transitory, response .
It has also been demonstrated that IL-6 antisense oligonucleotides can inhibit the growth of human myeloma cell lines . Very recent work has shown that gamma-interferon can inhibit several IL-6-dependent biologic processes by downregulating IL-6 receptor expression, and can completely inhibit four human myeloma cell lines that are dependent on exogenous IL-6 for growth .
Isolated monoclonal gammopathy, the so-called monoclonal gammopathy of undetermined significance (MGUS), is a preneoplastic syndrome that has been extensively studied. However, because of the asymptomatic nature of MGUS, it is unknown whether this syndrome always precedes myeloma. Natural history studies by Kyle have demonstrated that after a median follow-up of 22 years, approximately 25% of patients with MGUS will develop myeloma, amyloidosis, or another lymphoproliferative disease .
Extramedullary plasmacytomas and solitary plasmacytomas of bone are two other syndromes that have the propensity to develop into myeloma. The further study of preneoplastic lesions should help elucidate factors necessary for tumor progression, as well as potential targets for intervention.
1. Riedel DA, Pottern L: The epidemiology of multiple myeloma. Hematol Oncol Clin North Am 6(2):225-247, 1992.
2. National Cancer Institute: 1973-1989 Annual Cancer Statistics Review. NCI, NIH, publication 92-2789, Bethesda, 1992.
3. Pottern L: Etiology and epidemiology of multiple myeloma and related disorders, in Wiernik PH, Canellos GP, et al (eds): Neoplastic Diseases of the Blood, pp 414-429. New York, Churchill Livingstone, 1985.
4. Potter M: Myeloma proteins (M-components) with antibody-like activity. N Engl J Med 284(15):831-838, 1974.
5. Byrd LG, McDonald AH, Gold LG, et al: Specific pathogen free BALB/cAn mice are refractory to plasmacytoma induction by pristane. J Immunol 147:3632, 1991.
6. Van Riet I, Heirman C, Lacor P, et al: Detection of monoclonal B lymphocytes in bone marrow and peripheral blood of multiple myeloma patients by immunoglobulin gene rearrangement. Br J Haematol 73:289-295, 1989.
7. Bird JM, Russell NH, Samson D: Minimal residual disease after bone marrow transplantation for multiple myeloma. Bone Marrow Transplant 12:651-654, 1993.
8. Berenson J, Lichtenstein A: Clonal rearrangement of the beta-T cell receptor gene in multiple myeloma. Leukemia 3(2):133-136, 1989.
9. Massaia M, Attisano C, Peola S, et al: Rapid generation of antiplasma cell activity in the bone marrow of myeloma patients by CD3-activated T cells. Blood 82(6):1787-1797, 1993.
10. Brandt SJ, Bodine DB, Dunbar CE, et al: Dysregulated interleukin-6 expression produces a syndrome resembling Castleman's disease in mice. J Clin Invest 86:592-599, 1990.
11. Zhang XG, Klein B, Bataille R: IL-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood 74:11-13, 1989.
12. Kawano M, Hirano T, Matsude T, et al: Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332:83-85, 1988.
13. Klein B, Zhang XG, Jourdan M, et al: Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by IL-6. Blood 73:517-526, 1989.
14. Klein B, Wijdenes J, Zhang XG, et al: Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 78(5):1198-1204, 1991.
15. Levy Y, Tsapis A, Brouet JC: IL-6 antisense oligonucleotides inhibit the growth of human myeloma cell lines. J Clin Invest 88:696, 1991.
16. Portier M, Zhang XG, Caron E, et al: Gamma-interferon in multiple myeloma. Blood 81(11):3076-3082, 1993.
17. Kyle RA: "Benign" monoclonal gammopathy-after 20 to 35 years of follow-up. Mayo Clin Proc 68(1):26-36, 1993.
18. Facon T, Lai JL, Trillot N, et al: Cytogenetic analysis of bone marrow plasma cells after cytokine stimulation in patients with multiple myeloma. Blood 82(10, suppl 1):1028, 1993.
19. Travis P, Kaushal V, Baltz B, et al: Abnormal c-myc transcript size in 70% of patients with multiple myeloma. Blood 82(10, suppl 1):1030, 1993.
20. Selvanayagam P, Blick M, Narni F, et al: Alteration and abnormal expression of the c-myc oncogene in human multiple myeloma. Blood 71:30, 1988.
21. Seremetis S, Inghirami G, Ferrero D, et al: Transformation and plasmacytoid differentiation of EBV-infected human B lymphoblasts by ras oncogenes. Science 243(4891):660-663, 1989.
22. Neri A, Murphy JP, Cro L, et al: Ras oncogene mutation in multiple myeloma. J Exp Med 170(5):1715-1725, 1989.
23. Neri A, Baldini L, Trecca D, et al: p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood 81(1):128-135, 1993.
24. Portier M, Moles JP, Mazars GR, et al: p53 and RAS gene mutations in multiple myeloma. Oncogene 7(12):2539-2543, 1992.
25. Knudson AG Jr: Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci USA 68(4):820-823, 1971.
26. Tricot G, Dao D, Gazitt Y, et al: Deletion of the retinoblastoma gene in multiple myeloma. Blood 82(10, suppl 1):1029, 1993.
27. Pettersson M, Jernberg-Wiklund H, Larsson LG, et al: Expression of the bcl-2 gene in human multiple myeloma cell lines and normal plasma cells. Blood 79(2):495-502, 1992.
28. Korsmeyer S: Bcl-2 initiates a new category of oncogenes: Regulators of cell death. Blood 80(4):879-886, 1992.
29. McDonnell TJ, Korsmeyer SJ: Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18). Nature 349:254-256, 1991.
30. van Hoeven KH, Reed LJ, Factor SM: Autopsy-documented cure of multiple myeloma 14 years after M2 chemo. Cancer 66:1472, 1990.
31. Gregory WM, Richards MA, Malpas JS: Combination chemotherapy vs melphalan and prednisolone in the treatment of multiple myeloma. J Clin Oncol 10(2):334-342, 1992.
32. Barlogie B, Smith L, Alexanian R: Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 310:1353-1356, 1984.
33. Alexanian R, Barlogie B, Dixon D: High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med 105:8-11, 1986.
34. Grogan TM, Spier CM, Salmon SE, et al: P-glycoprotein expression in human plasma cell myeloma. Blood 81(2):490-495, 1993.
35. Tsuruo T, Iida H, Tsukagoshi S, et al: Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41:1967-1972, 1981.
36. Dalton WS, Grogan TM, Meltzer PS, et al: Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol 7(4):415-424, 1989.
37. Moalli PA, Pillay S, Weiner D, et al: A mechanism of resistance to glucocorticoids in multiple myeloma. Blood 79(1):213-222, 1992.
38. Gahrton G, Tura S, Ljungman P, et al: Allogeneic bone marrow transplantation in multiple myeloma. N Engl J Med 325(18):1267-1273, 1991.
39. Buckner CD, Fefer A, Bensinger WI, et al: Marrow transplantation for malignant plasma cell disorders. Eur J Haematol 43(51, suppl):186, 1989.
40. Vesole DH, Jagannath S, Glenn LD, et al: Allogeneic BMT in multiple myeloma. Proc Am Soc Clin Oncol 12:A1386, 1993.
41. Barlogie B, Jagannath S, Dixon D, et al: High dose melphalan and GM-CSF for refractory multiple myeloma. Blood 76:677-680, 1990.
42. McElwain TJ, Powles RL: High-dose intravenous melphalan for plasma-cell leukemia and myeloma. Lancet 1:822-823, 1983.
43. Barlogie B, Alexanian R, Dicke KA, et al: High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 70:869-872, 1987.
44. Gore ME, Selby PJ, Viner C, et al: Intensive treatment of multiple myeloma and criteria for complete remission. Lancet 2(8668):879-881, 1989.
45. Iurlo A, Mecucci C, Van Orshoven A: Cytogenetic and clinical investigations in 76 cases with therapy-related leukemia and myelodysplastic syndrome. Cancer Genet Cytogenet 43(2):227-241, 1989.
46. Jagannath S, Barlogie B, Dicke K, et al: Autologous bone marrow transplantation in multiple myeloma: Identification of prognostic factors. Blood 76(9):1860-1866, 1990.
47. Attal M, Harousseau JL, Stoppa AM, et al: High dose therapy in multiple myeloma: A prospective randomized study of the "Intergroupe Francais Du Myelome" (IFM). Blood 82(10, suppl 1):776, 1993.
48. Schiller G, Vescio R, Lee M, et al: Transplantation of autologous CD34-positive peripheral blood stem cells as treatment for multiple myeloma. Blood 82(10, suppl 1):778, 1993.
49. Siena S, Bregni M, Brando B: Circulation of CD34(+) hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: Enhancement by intravenous recombinant human granulocyte-macrophage CSF. Blood 74:1905-1914, 1989.
50. Vose J, Armitage J, Kessinger A: High-dose chemotherapy and autologous transplant with peripheral-blood stem cells. Oncology 7(8):23-29, 1993.
51. Fermand JP, Chevret S, Ravaud P, et al: High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: Results of a phase II trial involving 63 patients. Blood 82(7):2005-2009, 1993.
52. Koller M, Emerson S, Palsson B: Large-scale expansion of human stem and progenitor cells from bone marrow mononuclear cells in continuous perfusion cultures. Blood 82(2):378-384, 1993.
53. Turhan AG, Humphries RK, Eaves CJ, et al: Detection of breakpoint cluster region-negative and monoclonal hematopoiesis in vitro and in vivo after transplantation of cell selected in cultures of chronic myeloid leukemia marrow. Blood 76(11):2404-2410, 1990.
54. Montuoro A, De Rosa L, De Blasio A, et al: Alpha-2a interferon/melphalan/prednisone versus melphalan/prednisone in previously untreated patients with multiple myeloma. Br J Haematol 76:365, 1990.
55. Costanzi JJ, Cooper R, Scarffe JH, et al: Phase II study of recombinant alpha-2 interferon in resistant multiple myeloma. J Clin Oncol 3(5):654, 1985.
56. Quesada JR, Alexanian R, Hawkins M, et al: Treatment of multiple myeloma with recombinant alpha-interferon. Blood 67(2):275, 1986.
57. Mandelli F, Avvisati G, Amadori S, et al: Maintenance treatment with recombinant interferon alpha-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 322:1430-1435, 1990.